Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with or without cisplatin + fluoropyrimidine versus placebo + cisplatin + fluoropyrimidine in first-line advanced gastric or gastroesophageal junction adenocarcinoma
NL-OMON55397Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of pembrolizumab, cisplatin, fluorouracil and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Feb 2016; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON55397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55397.